4,143 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Acquired by Duality Advisers LP

Duality Advisers LP purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, Holdings Channel.com reports. The firm purchased 4,143 shares of the medical research company’s stock, valued at approximately $1,501,000.

Several other hedge funds have also bought and sold shares of TMO. Copper Rock Capital Partners LLC bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $265,775,000. Capital World Investors boosted its position in Thermo Fisher Scientific by 8.0% during the first quarter. Capital World Investors now owns 16,824,726 shares of the medical research company’s stock valued at $4,771,494,000 after buying an additional 1,242,140 shares during the period. Fisher Asset Management LLC grew its stake in shares of Thermo Fisher Scientific by 55,392.1% during the first quarter. Fisher Asset Management LLC now owns 944,476 shares of the medical research company’s stock valued at $267,853,000 after buying an additional 942,774 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of Thermo Fisher Scientific by 30.6% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,217,273 shares of the medical research company’s stock worth $628,819,000 after buying an additional 519,525 shares during the period. Finally, Girard Partners LTD. lifted its stake in shares of Thermo Fisher Scientific by 2,841.5% in the 1st quarter. Girard Partners LTD. now owns 528,475 shares of the medical research company’s stock valued at $5,506,000 after acquiring an additional 510,509 shares during the last quarter. 87.51% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CEO Marc N. Casper sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $411.05, for a total value of $8,221,000.00. Following the sale, the chief executive officer now directly owns 260,446 shares of the company’s stock, valued at approximately $107,056,328.30. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $348.00, for a total value of $870,000.00. Following the transaction, the chief financial officer now directly owns 37,989 shares of the company’s stock, valued at approximately $13,220,172. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 171,031 shares of company stock worth $67,284,857. Company insiders own 0.44% of the company’s stock.

A number of equities analysts have commented on TMO shares. Stifel Nicolaus lifted their price target on Thermo Fisher Scientific from $370.00 to $460.00 and gave the stock a “buy” rating in a research note on Thursday, July 23rd. Argus lifted their target price on shares of Thermo Fisher Scientific from $370.00 to $450.00 in a research note on Monday, July 27th. UBS Group increased their price target on shares of Thermo Fisher Scientific from $385.00 to $440.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Citigroup boosted their price objective on shares of Thermo Fisher Scientific from $390.00 to $471.00 and gave the company a “buy” rating in a research report on Thursday, July 23rd. Finally, Needham & Company LLC increased their target price on shares of Thermo Fisher Scientific from $415.00 to $468.00 and gave the stock a “buy” rating in a report on Thursday, July 23rd. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $420.50.

Shares of TMO opened at $413.95 on Friday. The company has a 50-day simple moving average of $373.97 and a two-hundred day simple moving average of $335.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.62 and a quick ratio of 2.02. The firm has a market capitalization of $163.49 billion, a PE ratio of 44.80, a price-to-earnings-growth ratio of 1.85 and a beta of 1.04. Thermo Fisher Scientific Inc. has a one year low of $250.21 and a one year high of $420.99.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 22nd. The medical research company reported $3.89 EPS for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.22. Thermo Fisher Scientific had a return on equity of 18.18% and a net margin of 14.12%. The company had revenue of $6.92 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter last year, the business posted $3.04 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 14.95 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 0.21%. The ex-dividend date of this dividend is Monday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 7.13%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: How to Invest in an Index Fund

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.